First Time Loading...

Allakos Inc
NASDAQ:ALLK

Watchlist Manager
Allakos Inc Logo
Allakos Inc
NASDAQ:ALLK
Watchlist
Price: 1.05 USD -0.94% Market Closed
Updated: Apr 24, 2024

Intrinsic Value

ALLK's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Allakos, Inc. engages in the development of therapeutic antibodies. [ Read More ]

The intrinsic value of one ALLK stock under the Base Case scenario is 1.94 USD. Compared to the current market price of 1.05 USD, Allakos Inc is Undervalued by 46%.

Key Points:
ALLK Intrinsic Value
Base Case
1.94 USD
Undervaluation 46%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Allakos Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ALLK stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Allakos Inc

Provide an overview of the primary business activities
of Allakos Inc.

What unique competitive advantages
does Allakos Inc hold over its rivals?

What risks and challenges
does Allakos Inc face in the near future?

Has there been any significant insider trading activity
in Allakos Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Allakos Inc.

Provide P/S
for Allakos Inc.

Provide P/E
for Allakos Inc.

Provide P/OCF
for Allakos Inc.

Provide P/FCFE
for Allakos Inc.

Provide P/B
for Allakos Inc.

Provide EV/S
for Allakos Inc.

Provide EV/GP
for Allakos Inc.

Provide EV/EBITDA
for Allakos Inc.

Provide EV/EBIT
for Allakos Inc.

Provide EV/OCF
for Allakos Inc.

Provide EV/FCFF
for Allakos Inc.

Provide EV/IC
for Allakos Inc.

Show me price targets
for Allakos Inc made by professional analysts.

What are the Revenue projections
for Allakos Inc?

How accurate were the past Revenue estimates
for Allakos Inc?

What are the Net Income projections
for Allakos Inc?

How accurate were the past Net Income estimates
for Allakos Inc?

What are the EPS projections
for Allakos Inc?

How accurate were the past EPS estimates
for Allakos Inc?

What are the EBIT projections
for Allakos Inc?

How accurate were the past EBIT estimates
for Allakos Inc?

Compare the revenue forecasts
for Allakos Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Allakos Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Allakos Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Allakos Inc compared to its peers.

Compare the P/E ratios
of Allakos Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Allakos Inc with its peers.

Analyze the financial leverage
of Allakos Inc compared to its main competitors.

Show all profitability ratios
for Allakos Inc.

Provide ROE
for Allakos Inc.

Provide ROA
for Allakos Inc.

Provide ROIC
for Allakos Inc.

Provide ROCE
for Allakos Inc.

Provide Gross Margin
for Allakos Inc.

Provide Operating Margin
for Allakos Inc.

Provide Net Margin
for Allakos Inc.

Provide FCF Margin
for Allakos Inc.

Show all solvency ratios
for Allakos Inc.

Provide D/E Ratio
for Allakos Inc.

Provide D/A Ratio
for Allakos Inc.

Provide Interest Coverage Ratio
for Allakos Inc.

Provide Altman Z-Score Ratio
for Allakos Inc.

Provide Quick Ratio
for Allakos Inc.

Provide Current Ratio
for Allakos Inc.

Provide Cash Ratio
for Allakos Inc.

What is the historical Revenue growth
over the last 5 years for Allakos Inc?

What is the historical Net Income growth
over the last 5 years for Allakos Inc?

What is the current Free Cash Flow
of Allakos Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Allakos Inc.

Financials

Balance Sheet Decomposition
Allakos Inc

Current Assets 179.9m
Cash & Short-Term Investments 170.8m
Other Current Assets 9.1m
Non-Current Assets 63.7m
PP&E 57.5m
Other Non-Current Assets 6.2m
Current Liabilities 36.6m
Accounts Payable 1.8m
Accrued Liabilities 34.2m
Other Current Liabilities 628k
Non-Current Liabilities 38.2m
Other Non-Current Liabilities 38.2m
Efficiency

Earnings Waterfall
Allakos Inc

Revenue
0 USD
Operating Expenses
-196.1m USD
Operating Income
-196.1m USD
Other Expenses
10.4m USD
Net Income
-185.7m USD

Free Cash Flow Analysis
Allakos Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

ALLK Profitability Score
Profitability Due Diligence

Allakos Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Allakos Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

ALLK Solvency Score
Solvency Due Diligence

Allakos Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
59/100
Solvency
Score

Allakos Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALLK Price Targets Summary
Allakos Inc

Wall Street analysts forecast ALLK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALLK is 2.96 USD with a low forecast of 1.01 USD and a high forecast of 7.35 USD.

Lowest
Price Target
1.01 USD
4% Downside
Average
Price Target
2.96 USD
182% Upside
Highest
Price Target
7.35 USD
600% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ALLK Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ALLK Price
Allakos Inc

1M 1M
-20%
6M 6M
-43%
1Y 1Y
-77%
3Y 3Y
-99%
5Y 5Y
-97%
10Y 10Y
-97%
Annual Price Range
1.05
52w Low
1.02
52w High
5.55
Price Metrics
Average Annual Return 19.94%
Standard Deviation of Annual Returns 100.12%
Max Drawdown -99%
Shares Statistics
Market Capitalization 92.1m USD
Shares Outstanding 87 874 000
Percentage of Shares Shorted 8.29%

ALLK Return Decomposition
Main factors of price return

What is price return decomposition?

ALLK News

Last Important Events
Allakos Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Allakos Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Allakos Inc Logo
Allakos Inc

Country

United States of America

Industry

Biotechnology

Market Cap

92.1m USD

Dividend Yield

0%

Description

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Redwood City, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Contact

CALIFORNIA
Redwood City
975 Island Dr Ste 201
+16505975002.0
http://www.allakos.com/

IPO

2018-07-19

Employees

192

Officers

CEO & Director
Dr. Robert Alexander Ph.D.
President
Dr. Adam L. Tomasi Ph.D.
Chief Financial Officer
Mr. Baird Radford III
Chief Technical Officer
Ms. Mary Cromwell Ph.D.
Chief Medical Officer
Dr. Chin Lee M.D., M.P.H.
Director of Medical Affairs & Data Analytics
Mr. Alan Chang

See Also

Discover More
What is the Intrinsic Value of one ALLK stock?

The intrinsic value of one ALLK stock under the Base Case scenario is 1.94 USD.

Is ALLK stock undervalued or overvalued?

Compared to the current market price of 1.05 USD, Allakos Inc is Undervalued by 46%.